Hiroyuki Shimada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hiroyuki Shimada has a total of 181 co-authors. Here are the top co-authors by number of shared publications:
- Bill Chiu
Division of Pediatric Surgery, Department of Surgery, Stanford University, Palo Alto, USA
27 shared publications - Balint Forgo
Department of Pathology, Stanford University, Stanford, California
19 shared publications - Bo He
Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California
19 shared publications - Jiangbin Ye
Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA
19 shared publications - Joshua J. Gruber
UT Southwestern Medical Center 1 Hematology-Oncology, Internal Medicine Dallas, Texas
19 shared publications - Rachel L. Greathouse
Department of Surgery, Stanford University School of Medicine, Stanford, California
19 shared publications
Latest Publications
- 3 November 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
Feasibility and Tolerability of Chemoimmunotherapy Given During Induction for Treatment of Patients With High-Risk Neuroblastoma: A Report From the Children's Oncology Group
Purpose: The addition of the anti-GD2 antibody dinutuximab (DIN) to postconsolidation therapy led to improved event-free survival (EFS) for patients with high-risk neuroblastoma (HRNBL). The combination of DIN with chemotherapy (chemoimmunotherapy) results in objective responses in patients with recurrent/refractory neuroblastoma. We evaluated the feasibility of administering chemoimmunotherapy during induction for HRNBL in a multicenter trial. Methods: Children's Oncology Group (COG) ANBL17P1 was a prospective, single-arm, limited institution pilot study to assess tolerability and feasibility of administering DIN and sargramostim with induction chemotherapy cycles 3-5. The primary end point of tolerability was assessed as the occurrence of a predefined unacceptable toxicity or toxic death during DIN-containing cycles. Feasibility was assessed as ability to receive ≥75% of planned DIN doses. Revised International Neuroblastoma Response Criteria were used to assess response. Results: Forty eligible, evaluable patients with newly diagnosed HRNBL were enrolled at eight sites from January 2019 to June 2020. The most common DIN-related grade ≥3 toxicities during induction cycles 3-5 included fever (30.0%) and pain (7.5%). There were no unacceptable toxicities or toxic deaths during induction cycles 3-5. Patients received 92.0%-101.8% of intended induction DIN doses. This regimen was therefore deemed both feasible and tolerable. Thirty-seven patients completed all end-of-induction evaluations; 13 had complete response (CR), 22 partial response (PR), one minor response (MR), zero stable disease, and one progressive disease. The overall end of induction CR + PR rate was 87.5%. The 3-year EFS was 52.5% ± 7.9%. Conclusion: Administration of DIN with COG induction cycles 3-5 for patients with newly diagnosed HRNBL was tolerable and feasible. This approach is currently being evaluated in a COG randomized phase III trial.
- 3 November 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
Feasibility and Tolerability of Chemoimmunotherapy Given During Induction for Treatment of Patients With High-Risk Neuroblastoma: A Report From the Children's Oncology Group
Purpose: The addition of the anti-GD2 antibody dinutuximab (DIN) to postconsolidation therapy led to improved event-free survival (EFS) for patients with high-risk neuroblastoma (HRNBL). The combination of DIN with chemotherapy (chemoimmunotherapy) results in objective responses in patients with recurrent/refractory neuroblastoma. We evaluated the feasibility of administering chemoimmunotherapy during induction for HRNBL in a multicenter trial. Methods: Children's Oncology Group (COG) ANBL17P1 was a prospective, single-arm, limited institution pilot study to assess tolerability and feasibility of administering DIN and sargramostim with induction chemotherapy cycles 3-5. The primary end point of tolerability was assessed as the occurrence of a predefined unacceptable toxicity or toxic death during DIN-containing cycles. Feasibility was assessed as ability to receive ≥75% of planned DIN doses. Revised International Neuroblastoma Response Criteria were used to assess response. Results: Forty eligible, evaluable patients with newly diagnosed HRNBL were enrolled at eight sites from January 2019 to June 2020. The most common DIN-related grade ≥3 toxicities during induction cycles 3-5 included fever (30.0%) and pain (7.5%). There were no unacceptable toxicities or toxic deaths during induction cycles 3-5. Patients received 92.0%-101.8% of intended induction DIN doses. This regimen was therefore deemed both feasible and tolerable. Thirty-seven patients completed all end-of-induction evaluations; 13 had complete response (CR), 22 partial response (PR), one minor response (MR), zero stable disease, and one progressive disease. The overall end of induction CR + PR rate was 87.5%. The 3-year EFS was 52.5% ± 7.9%. Conclusion: Administration of DIN with COG induction cycles 3-5 for patients with newly diagnosed HRNBL was tolerable and feasible. This approach is currently being evaluated in a COG randomized phase III trial.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
Statistical Framework of INPC-Risk Grouping System
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
Statistical Framework of INPC-Risk Grouping System
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Data from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
Purpose:Historically, neuroblastoma risk stratification has been performed with clinical stage as the starting point and successively adding other prognostic factors thereafter. This study takes an alternative approach to define risk groups of patients with neuroblastoma by starting with the International Neuroblastoma Pathology Classification (INPC).Experimental Design:The cohort of patients with neuroblastoma previously used for developing the Children’s Oncology Group–Revised Neuroblastoma Risk Classification (RNRC) system was reanalyzed by survival tree regression analysis, starting with the INPC distinguishing favorable-histology and unfavorable-histology categories. The resultant two branches were further divided first by the International Neuroblastoma Risk Group Staging System and successively by other prognostic factors.Results:This new stratification system, the INPC-Risk Grouping (INPC-RG), is simpler than the RNRC system, eliminating unnecessary decision trees, and distinguishes four risk groups (groups I–IV). Using only INPC (unfavorable histology) and International Neuroblastoma Risk Group Staging System (stage M), INPC-RG defines patients with highly aggressive group IV tumors, whose 5-year event-free survival was worse than that of the RNRC high-risk group. Additionally, it identifies group III patients whose 5-year event-free survival spanned 50% to 80%, which was not identified by the RNRC.Conclusions:The benefits of using this new INPC-RG system are fourfold: (1) it allows for the rapid identification of group IV patients, (2) it lays the foundation for further refinement of group III, (3) it can stratify patients when the amount of tumor tissue is limited, and (4) it allows patients in resource-limited areas to be appropriately stratified, potentially improving the worldwide treatment of patients with neuroblastoma.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
Purpose:Historically, neuroblastoma risk stratification has been performed with clinical stage as the starting point and successively adding other prognostic factors thereafter. This study takes an alternative approach to define risk groups of patients with neuroblastoma by starting with the International Neuroblastoma Pathology Classification (INPC).Experimental Design:The cohort of patients with neuroblastoma previously used for developing the Children’s Oncology Group–Revised Neuroblastoma Risk Classification (RNRC) system was reanalyzed by survival tree regression analysis, starting with the INPC distinguishing favorable-histology and unfavorable-histology categories. The resultant two branches were further divided first by the International Neuroblastoma Risk Group Staging System and successively by other prognostic factors.Results:This new stratification system, the INPC-Risk Grouping (INPC-RG), is simpler than the RNRC system, eliminating unnecessary decision trees, and distinguishes four risk groups (groups I–IV). Using only INPC (unfavorable histology) and International Neuroblastoma Risk Group Staging System (stage M), INPC-RG defines patients with highly aggressive group IV tumors, whose 5-year event-free survival was worse than that of the RNRC high-risk group. Additionally, it identifies group III patients whose 5-year event-free survival spanned 50% to 80%, which was not identified by the RNRC.Conclusions:The benefits of using this new INPC-RG system are fourfold: (1) it allows for the rapid identification of group IV patients, (2) it lays the foundation for further refinement of group III, (3) it can stratify patients when the amount of tumor tissue is limited, and (4) it allows patients in resource-limited areas to be appropriately stratified, potentially improving the worldwide treatment of patients with neuroblastoma.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
International Neuroblastoma Pathology Classification.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
International Neuroblastoma Pathology Classification.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
Children’s Oncology Group Revised Neuroblastoma Risk Classification.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
Children’s Oncology Group Revised Neuroblastoma Risk Classification.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 4 from Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma
Primers for p53 mutation analysis
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 4 from Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma
Primers for p53 mutation analysis
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma
Regional counting of differential methylated probes in SK-N-BE(2) cells treated with NEN for 24hrs under nomoxia. Go enrichment pathways of the differential methylated probes of the CpG Island in the promoter (B) (C) and gene body (D) (E)
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma
Regional counting of differential methylated probes in SK-N-BE(2) cells treated with NEN for 24hrs under nomoxia. Go enrichment pathways of the differential methylated probes of the CpG Island in the promoter (B) (C) and gene body (D) (E)
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 3 from Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma
Favorable and (B) unfavorable gene list (p-value<0.05) from 11 available neuroblastoma databases from R2 (https://hgserver1.amc.nl/cgi-bin/r2/main.cgi) (C) Overlapped the favorable prognosis gene sets (p-value1000) from 7 available neuroblastoma databases from R2 (https://hgserver1.amc.nl/cgi-bin/r2/main.cgi). (D) (E) Go analysis of overlapped favorable and unfavorable prognosis gene sets. (F) (G) GSEA analysis of Favorable and unfavorable gene list genes from RNA-seq experiments in Figure (1D).
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 3 from Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma
Favorable and (B) unfavorable gene list (p-value<0.05) from 11 available neuroblastoma databases from R2 (https://hgserver1.amc.nl/cgi-bin/r2/main.cgi) (C) Overlapped the favorable prognosis gene sets (p-value1000) from 7 available neuroblastoma databases from R2 (https://hgserver1.amc.nl/cgi-bin/r2/main.cgi). (D) (E) Go analysis of overlapped favorable and unfavorable prognosis gene sets. (F) (G) GSEA analysis of Favorable and unfavorable gene list genes from RNA-seq experiments in Figure (1D).
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma
SK-N-BE(2) cells were treated with NEN for 16hrs. (A) Upregulated and (B) downregulated genes from RNA-seq data (n=3) (sleuth q-value < 0.05 and fold change estimate b > abs(ln(2))). (C) The top 10 gene ontology (GO) pathways enriched from upregulated genes by using DAVID analysis. (D) The top 10 gene ontology (GO) pathways enriched from downregulated genes by using DAVID analysis.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma
SK-N-BE(2) cells were treated with NEN for 16hrs. (A) Upregulated and (B) downregulated genes from RNA-seq data (n=3) (sleuth q-value < 0.05 and fold change estimate b > abs(ln(2))). (C) The top 10 gene ontology (GO) pathways enriched from upregulated genes by using DAVID analysis. (D) The top 10 gene ontology (GO) pathways enriched from downregulated genes by using DAVID analysis.